Field safety notices: Accriva Diagnostics, Inc.
Manufacturer registered in EUDAMED: SRN US-MF-000009902 ; country: United States
4 authority publications by 2 authorities, from 11 Feb 2020 to 9 Jun 2026.
Latest notice: 9 Jun 2026, ANSM, Réactif DirectCheck ACT-LR Whole Blood Controls, Level 2
Uneven depth of sources: BfArM followed since March 2026, MHRA since January 2025, IGJ fully since 2026, BASG partial. The absence of a notice before these dates proves nothing. A notice repeated by several authorities appears once per authority. Independent page, neither published nor endorsed by Accriva Diagnostics, Inc. or by any authority; a matching error can be reported through the legal notice page and is corrected within two working days.
2 distinct corrective actions.
Corrective action: 2 publications by AEMPS, ANSM, from 26 May 2026 to 9 Jun 2026
- ANSMFranceofficial source: Réactif DirectCheck ACT-LR Whole Blood Controls, Level 2, ANSM, 2026-06-09Réactif DirectCheck ACT-LR Whole Blood Controls, Level 2
Source : ANSM, informations de sécurité · collected 16 Nov 2026
- Controles de calidad de sangre total directCHECK ACT-LR, Nivel 2. Referencia: DCGLR-2Models, lots, UDI: UDI-DI: 10711234170373
Fuente: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios), alertas de productos sanitarios · collected 17 Nov 2026
Corrective action: 2 publications by AEMPS, ANSM, from 11 Feb 2020 to 28 Feb 2020
- AEMPSSpainofficial source: Hemochron Signature Elite. Referencias: ELITE, ELITEINT, AEMPS, 2020-02-28Hemochron Signature Elite. Referencias: ELITE, ELITEINT
Fuente: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios), alertas de productos sanitarios · collected 17 Nov 2026
- Automate Hemochron Signature Elite
Source : ANSM, informations de sécurité · collected 16 Nov 2026